메뉴 건너뛰기




Volumn 15, Issue 12, 2013, Pages 874-877

Commentary in Support of a Highly Effective Hypertension Treatment Algorithm

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL HYDROCHLOROTHIAZIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

EID: 84888870870     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12182     Document Type: Note
Times cited : (6)

References (30)
  • 1
    • 0347423198 scopus 로고    scopus 로고
    • National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report
    • et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    • Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report. Hypertension. 2003;42:1206-1252.
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 2
    • 80052662775 scopus 로고    scopus 로고
    • National Clinical Guideline Centre. London, UK:National Institute for Health and Clinical Excellence (NICE); (Clinical guideline; no. 127).
    • National Clinical Guideline Centre. Hypertension. Clinical Management of Primary Hypertension in Adults. London, UK:National Institute for Health and Clinical Excellence (NICE); 2011. 36 (Clinical guideline; no. 127).
    • (2011) Hypertension. Clinical Management of Primary Hypertension in Adults , pp. 36
  • 3
    • 84860911103 scopus 로고    scopus 로고
    • The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy
    • Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012;28:27.
    • (2012) Can J Cardiol , vol.28 , pp. 27
    • Daskalopoulou, S.S.1    Khan, N.A.2    Quinn, R.R.3
  • 4
    • 84888866358 scopus 로고    scopus 로고
    • ® 2012. Available at: (Accessed June 18, 2013).
    • ® 2012. Available at: http://www.ncqa.org/HEDISQualityMeasurement/QualityMeasurementProducts/QualityCompass.aspx (Accessed June 18, 2013).
  • 5
    • 64849106873 scopus 로고    scopus 로고
    • A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial
    • Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial. Hypertension. 2009;53:646-653.
    • (2009) Hypertension , vol.53 , pp. 646-653
    • Feldman, R.D.1    Zou, G.Y.2    Vandervoort, M.K.3
  • 7
    • 79551664955 scopus 로고    scopus 로고
    • Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema
    • Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128-135.
    • (2011) Am J Med , vol.124 , pp. 128-135
    • Makani, H.1    Bangalore, S.2    Romero, J.3
  • 8
    • 57349138291 scopus 로고    scopus 로고
    • Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    • Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
    • (2008) N Engl J Med , vol.359 , pp. 2417-2428
    • Jamerson, K.1    Weber, M.A.2    Bakris, G.L.3
  • 9
    • 0034729993 scopus 로고    scopus 로고
    • Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in Hypertension Treatment (INSIGHT)
    • Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
    • (2000) Lancet , vol.356 , pp. 366-372
    • Brown, M.J.1    Palmer, C.R.2    Castaigne, A.3
  • 10
    • 77954191608 scopus 로고    scopus 로고
    • 24-hour ambulatory blood pressure in the ACCOMPLISH trial
    • Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010;363:98.
    • (2010) N Engl J Med , vol.363 , pp. 98
    • Jamerson, K.A.1    Bakris, G.L.2    Weber, M.A.3
  • 11
    • 77953577951 scopus 로고    scopus 로고
    • Population trends in the incidence and outcomes of acute myocardial infarction
    • Yeh RW, Sidney S, Chandra MBA, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155-2165.
    • (2010) N Engl J Med , vol.362 , pp. 2155-2165
    • Yeh, R.W.1    Sidney, S.2    Chandra, M.B.A.3
  • 12
    • 84888878583 scopus 로고    scopus 로고
    • Closing the gap between cardiovascular and cancer mortality in an integrated health care delivery system, 2000-2008: the Kaiser Permanente experience
    • A13610.
    • Sidney S, Jaffe M, Nguyen-Huynh MN, et al. Closing the gap between cardiovascular and cancer mortality in an integrated health care delivery system, 2000-2008: the Kaiser Permanente experience. Circulation. 2008;124:21S; A13610.
    • (2008) Circulation , vol.124
    • Sidney, S.1    Jaffe, M.2    Nguyen-Huynh, M.N.3
  • 13
    • 3042819708 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines on hypertension antihypertensive agents in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI clinical practice guidelines on hypertension antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(Suppl 1):S1-S290.
    • (2004) Am J Kidney Dis , vol.43 , Issue.SUPPL. 1
  • 14
    • 56749184141 scopus 로고    scopus 로고
    • Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study
    • Fox CH, Swanson A, Kahn LS, et al. Improving chronic kidney disease care in primary care practices: an upstate New York practice-based research network (UNYNET) study. J Am Board Fam Med. 2008;21:522-530.
    • (2008) J Am Board Fam Med , vol.21 , pp. 522-530
    • Fox, C.H.1    Swanson, A.2    Kahn, L.S.3
  • 15
    • 15844407124 scopus 로고    scopus 로고
    • Systemic hypertension and nondiabetic chronic kidney disease: the best evidence-based therapeutic approach today
    • Jafar TH. Systemic hypertension and nondiabetic chronic kidney disease: the best evidence-based therapeutic approach today. Eur Rev Med Pharmacol Sci. 2005;9:1-12.
    • (2005) Eur Rev Med Pharmacol Sci , vol.9 , pp. 1-12
    • Jafar, T.H.1
  • 16
    • 84871995815 scopus 로고    scopus 로고
    • Standards of medical care in diabetes 2013
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
    • (2013) Diabetes Care , vol.36 , Issue.SUPPL. 1
  • 17
    • 33845760213 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines clinical practice recommendations for diabetes chronic kidney disease
    • KDOQI clinical practice guidelines clinical practice recommendations for diabetes chronic kidney disease. Am J Kidney Dis. 2007;49(Suppl 2):S12-S154.
    • (2007) Am J Kidney Dis , vol.49 , Issue.SUPPL. 2
  • 18
    • 57749202460 scopus 로고    scopus 로고
    • Initial combination therapy for rapid and effective control of moderate and severe hypertension
    • Franklin SS, Neutel JM. Initial combination therapy for rapid and effective control of moderate and severe hypertension. J Hum Hypertens. 2009;23:4-11.
    • (2009) J Hum Hypertens , vol.23 , pp. 4-11
    • Franklin, S.S.1    Neutel, J.M.2
  • 19
    • 77957877218 scopus 로고    scopus 로고
    • BP trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed CAD patients
    • Maddox TM, Ross C, Tavel HM, et al. BP trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed CAD patients. Circ Cardiovasc Qual Outcomes. 2010;3:347-357.
    • (2010) Circ Cardiovasc Qual Outcomes , vol.3 , pp. 347-357
    • Maddox, T.M.1    Ross, C.2    Tavel, H.M.3
  • 20
    • 15944409988 scopus 로고    scopus 로고
    • Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril
    • Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
    • (2005) JAMA , vol.293 , pp. 1595-1608
    • Wright, J.T.1    Dunn, J.K.2    Cutler, J.A.3
  • 21
    • 78149263066 scopus 로고    scopus 로고
    • Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement
    • Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks. An update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780-800.
    • (2010) Hypertension , vol.56 , pp. 780-800
    • Flack, J.M.1    Sica, D.A.2    Bakris, G.3
  • 22
    • 0020362658 scopus 로고
    • Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide
    • Veterans Administration Co-operative Study Group on Antihypertensive Agents
    • Veterans Administration Co-operative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14:97S-101S.
    • (1982) Br J Clin Pharmacol , vol.14
  • 23
    • 34047197931 scopus 로고    scopus 로고
    • Effect of spironolactone on blood pressure in subjects with resistant hypertension
    • Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
    • (2007) Hypertension , vol.49 , pp. 839-845
    • Chapman, N.1    Dobson, J.2    Wilson, S.3
  • 24
    • 49249106417 scopus 로고    scopus 로고
    • Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research
    • Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:1403-1419.
    • (2008) Hypertension , vol.51 , pp. 1403-1419
    • Calhoun, D.A.1    Jones, D.2    Textor, S.3
  • 25
    • 78049460820 scopus 로고    scopus 로고
    • Spironolactone management of resistant hypertension
    • Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother. 2010;44:1762-1768.
    • (2010) Ann Pharmacother , vol.44 , pp. 1762-1768
    • Marrs, J.C.1
  • 26
    • 84867100855 scopus 로고    scopus 로고
    • Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension
    • Handler J. Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. J Clin Hypertens (Greenwich). 2012;14:732-734.
    • (2012) J Clin Hypertens (Greenwich) , vol.14 , pp. 732-734
    • Handler, J.1
  • 27
    • 24644520481 scopus 로고    scopus 로고
    • Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone
    • Fujii H, Nakahama H, Yoshihara F, et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. Kobe J Med Sci. 2005;51:1-6.
    • (2005) Kobe J Med Sci , vol.51 , pp. 1-6
    • Fujii, H.1    Nakahama, H.2    Yoshihara, F.3
  • 28
    • 77956979633 scopus 로고    scopus 로고
    • Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study
    • Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27:1629-1651.
    • (2010) Chronobiol Int , vol.27 , pp. 1629-1651
    • Hermida, R.C.1    Ayala, D.E.2    Mojon, A.3    Fernandez, J.R.4
  • 29
    • 84867734437 scopus 로고    scopus 로고
    • Dosing frequency and medication adherence in chronic disease
    • Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527-539.
    • (2012) J Manag Care Pharm , vol.18 , pp. 527-539
    • Coleman, C.I.1    Limone, B.2    Sobieraj, D.M.3
  • 30
    • 44349111871 scopus 로고    scopus 로고
    • Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically complied dosing histories
    • Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically complied dosing histories. BMJ. 2008;336:1114-1117.
    • (2008) BMJ , vol.336 , pp. 1114-1117
    • Vrijens, B.1    Vincze, G.2    Kristanto, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.